Who should not take MT-1 (Melanotan I)?
Documented caution flags for MT-1 (Melanotan I) include personal history of melanoma and atypical mole syndrome. This is not exhaustive, and absence from this list is not a safety clearance. Anyone pregnant, nursing, or managing a serious medical condition should only consider it under a doctor's care, and safety data for MT-1 (Melanotan I) is limited.
Documented caution flags for MT-1 (Melanotan I)
- Personal history of melanoma
- Atypical mole syndrome
- Pregnancy / nursing
Reported side effects to weigh
- Nausea (first doses, usually fades)
- Facial flushing
- Appetite suppression
- Mole / freckle darkening (mole-map first)
References
- Afamelanotide for Erythropoietic Protoporphyria (Scenesse approval data) — Langendonk JG et al., NEJM, 2015
- Skin pigmentation and pharmacokinetics of melanotan-I in humans — Ugwu SO, Blanchard J, Dorr RT, Levine N, et al.; Biopharmaceutics & Drug Disposition; 1997
- Afamelanotide: An Orphan Drug with Potential for Broad Dermatologic Applications — Wu J, Cotliar R; Journal of Drugs in Dermatology; 2021
Pepdex is an editorial reference, not medical advice. Peptides vary in legal and approval status by country, many are research compounds without full human safety data. Talk to a qualified clinician before starting anything.
More on MT-1 (Melanotan I)
Full MT-1 (Melanotan I) breakdownMT-1 (Melanotan I) what it's used forMT-1 (Melanotan I) side effectsMT-1 (Melanotan I) how to take itMT-1 (Melanotan I) mistakes to avoidMT-1 (Melanotan I) half-lifeMT-1 (Melanotan I) how long to workMT-1 (Melanotan I) legal statusMT-1 (Melanotan I) how it worksmt 1 vs mt 2Ask the AI Coach
Last updated 2026-06-15.